Graham Tulloch
| Dr. Graham Tulloch, PhD. is Senior Director Upstream Process Development, Large Molecule API in the BioTherapeutics Development organization at Janssen Pharmaceutical Companies of Johnson and Johnson. Dr. Tulloch is responsible for upstream development of therapeutic protein manufacturing processes spanning early phase through product registration, transfer of ownership, and lifecycle management. Prior roles at Janssen include strategic responsibility for driving and maintaining scientific capability throughout BioTherapeutics Development with focus on biologics drug substance including therapeutic proteins and cell and gene therapy. This role encompassed strategic identification, characterization, and feasibility assessment of external innovation, academic outreach, and scientific due diligence for therapeutic assets and new technologies. Prior to joining Janssen, Dr Tulloch held scientific leadership roles and Merck, Eli Lilly and Biostar. In his last leadership role at Merck where he served as Director Keytruda Global Drug Substance Lead, he was responsible for manufacturing sciences, technology transfer, technical strategy, and 2nd generation process development to grow the Keytruda drug substance supply chain. While at Merck, Dr. Tulloch also built and led the Process Development and Commercialization organization that drove technical and scientific activities leading to the global marketing application approvals for both Keytruda and Zinplava. Prior to Merck, Dr. Tulloch worked at Eli Lilly in increasing technical and leadership roles in drug substance manufacturing, process development and commercialization of biologics. In his tenure at Biostar, Dr. Tulloch was responsible for early-stage process development, scale-up and tech transfer of biologic drug substance processes. Dr. Tulloch holds a BSc and a Ph.D. in biochemistry from University of Saskatchewan, Saskatoon SK CA. Dr. Tulloch also completed a post-doctoral fellowship at Harvard Medical School. |